Chemomab Therapeutics Ltd is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies for fibrotic and inflammatory diseases
Chemomab Therapeutics Ltd is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies for fibrotic and inflammatory diseases. Its lead candidate, CM-101, is a first-in-class monoclonal antibody targeting CCL24, currently advancing into phase II studies for liver, skin, and lung fibrosis.